Sage Journals: Discover world-class research

Abstract

Nonalcoholic fatty liver disease (NAFLD) is paralleling the insulin resistance and obesity epidemic and is regarded as liver metabolic syndrome, and its prevalence rate is increasing rapidly. The best explanation for the occurrence and development of NAFLD is the “multiple hit” hypothesis instead of the “two-hit” hypothesis. At present, NAFLD therapies are limited. The nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway is a key pathway in oxidative stress. Its downstream proteins/enzymes are regulated. Metabolic enzymes and antioxidant proteins/enzymes play a vital role in cell defense protection and have attracted attention in the field of antioxidant research in recent years. This paper summarizes the regulatory mechanism of the Nrf2 signaling pathway and the research progress of Nrf2 activators in NAFLD to provide guidance for NAFLD therapy in the future.

Keywords

chemical activators Nrf2 nonalcoholic fatty liver disease ARE

Nonalcoholic fatty liver disease (NAFLD) is a complicated chronic liver disease worldwide that is characterized by excessive fat accumulation in the liver.¹ The well-known explanation for the occurrence and development of NAFLD is the “multiple hit” hypothesis. Such hits include hormones excreted from adipose tissue, insulin resistance, nutritional factors, gut microbiota, and genetic and epigenetic factors. In the general population, there has been a growing amount of evidence indicating the high prevalence of NAFLD in the past 20 years. A recent meta-analysis predicted that the global prevalence of NAFLD had reached 25.2%, and in the Middle East and South America, it was 31.8% and 30.4%, respectively. In addition, the prevalence of NAFLD in Europe and Asia was verified to be 23.7% and 27.4%, respectively.² Therefore, the health problem of NAFLD has aroused wide public concern. Unfortunately, there are no effective treatments in the management of NAFLD despite the significant advances that have been made in illuminating the pathophysiology of NAFLD. Currently, lifestyle changes such as diet and exercise remain the primary treatment of NAFLD, which are mainly dependent on patient compliance.³ Because of the increasing NAFLD prevalence and the lack of effective treatment, it is urgently necessary to explore effective and safe treatments for patients with NAFLD.

Nuclear factor erythroid-derived 2-like 2 (Nrf2) is a transcription factor that contains a highly conserved basic region-leucine zipper (bZIP) structure. Nrf2 is a member of the Cap “n” Collar (CNC) family and plays a vital cytoprotective role in the activation of cellular antioxidant enzymes.^4,5 Furthermore, Nrf2 has also been shown to play a role in the resistance to oxidation and the regulation of lipid metabolism in models of NAFLD and remains a potential strategy in the prevention and therapy of NAFLD.⁶ Therefore, researchers have paid much attention to identifying Nrf2 activators, which may be used as protective agents for NAFLD.

Relationship Between NAFLD and the Nrf2 Pathway

NAFLD is a multifactorial chronic disease with a complex pathogenesis in which oxidative stress plays a key role.⁶ The pathologic spectrum of NAFLD ranges from steatosis to steatohepatitis, liver fibrosis, liver cirrhosis, and even hepatocellular carcinoma, and the common characteristic of the disease is the accumulation of lipid droplets in liver cells.⁷ Lipid storage in the liver is limited, but in patients with NAFLD, the storage capacity is surpassed, leading to hepatocyte dysfunction and death. Excessive oxidation of fatty acids promotes reactive oxygen species (ROS) generation in hepatic mitochondria, which become overburdened, leading to oxidative stress in the liver.⁸ Oxidative stress damages lipids, proteins, and DNA by activating proinflammatory cells such as Kupffer cells and stimulating the release of inflammatory cytokines. Furthermore, overloaded ROS may directly deplete the antioxidant capacity in the liver by reducing glutathione (GSH) and restraining the expression and activity of downstream antioxidant enzymes.^9,10 Finally, chronic inflammation and oxidative stress promote liver diseases, such as liver fibrosis, cirrhosis, and even hepatoma. In conclusion, reducing oxidative stress is expected to improve the progression of NAFLD.

The Kelch-like-ECH-associated protein 1 (Keap1)-Nrf2-antioxidative response element (ARE) signaling pathway is regarded as a vital antioxidative mechanism because of its ability to improve the oxidative stress response induced by internal or external oxidation and chemicals.¹¹ The Nrf2 gene contains 6 highly conserved epichlorohydrin (EHC) domains (Nrf2-EHC homology, Neh), named Neh1-6 (Figure 1).¹² The C-terminus of Neh1 contains the bZIP DNA region, which binds to the musculoaponeurotic fibrosarcoma protein (Maf) to form a heterodimer that binds to DNA and recognizes ARE. Neh2 contains 2 important conserved regions, DLG and ETGE, which bind to KEAP1 and then anchor Nrf2 to the cytoplasm.¹³ Neh3, which is located at the C-terminus and binds with a chromo-ATPase/helicase DNA-binding protein (CHD6), is closely related to ARE transcriptional activity.¹⁴ Neh4 and Neh5 act as transcriptional activators interacting with the cyclic adenosine monophosphate response element (CREB)-binding protein (CBP) and initiate transcription.¹⁵ The Neh6 region is rich in serine and is a regulatory region for Nrf2 degradation independent of KEAP1.¹⁶

Figure 1

The structure of Nrf2. ARE, antioxidative response element; CBP, CREB-binding protein; CREB, cyclicadenosine monophosphate response element; Keap1, Kelch-like-ECH-associated protein 1; Maf, musculoaponeurotic fibrosarcoma; Nrf2, nuclearfactor erythroid-derived 2-like 2.

The mechanism of action for Nrf2 has been reviewed in detail at present.¹⁷ Briefly, during homeostatic conditions, Nrf2 is also expressed but is located in the cytoplasm in combination with Keap1, which mediates the ubiquitinylation and degradation of Nrf2 (Figure 2). Upon exposure to oxidative or electrophilic stress, cysteine residues in Keap1 are modified¹⁸ and stimulate the release of Nrf2. The Nrf2 protein, which dissociates from Keap1, relocates to the nucleus and dimerizes with bZIP proteins such as Maf¹⁹ to bind with AREs and then promotes the expression of ARE-mediated downstream target genes, including hundreds of antioxidant and cytoprotective enzymes. NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1), and GSH are the most important antioxidant proteins among many downstream target proteins of Nrf2.

Figure 2

The regulation of the Nrf2/ARE signaling pathway. (a) Under homeostatic conditions, the Keap1 dimer binds with Nrf2 in the cytoplasm, leading to ubiquitination and then degradation of Nrf2. (b) Under oxidative or electrophilic stress, Keap1 is modified, and the capacity to bind Nrf2 is weaker. Nrf2 dissociates and transfers to the nucleus and binds with Maf to recognize AREs and stimulates the transcription of a series of class II metabolic enzymes, antioxidant proteins/enzymes, proteasome/molecular chaperones, anti-inflammatory factors, and phase III metabolic enzymes (drug transporters). ARE, antioxidative response element; Keap1, Kelch-like-ECH-associated protein 1; Maf, musculoaponeurotic fibrosarcoma; Nrf2, nuclearfactor erythroid-derived 2-like 2.

Nrf2 is pivotal for maintaining cellular redox homeostasis, providing protection against oxidative or electrophilic stresses, and suppressing NAFLD promotion and progression. In Nrf2^+/+ and Nrf2^−/− mice fed a high-fat diet (HFD), livers from Nrf2^−/− mice had a conspicuous increase in steatosis and suffered more oxidative stress than Nrf2^+/+ mice as assessed by a decrease in GSH and growing fatty acid accumulation compared with Nrf2^+/+ mice. Insulin resistance could be reversed in Nrf2^+/+ group mice treated with TBE-31, which is a new drug for NAFLD treatment, but not in Nrf2^−/− mice.^20
-22 Additionally, spontaneous dysfunction of the intestinal barrier and promotion of the inflammatory response to lipopolysaccharide (LPS) stimulated the development of nonalcoholic steatohepatitis (NASH) in Nrf2^−/− mice.²³ Bach1, a repressor of Nrf2, was upregulated because of hepatocyte-specific Sirt6 and was found to correlate with an increased risk of NAFLD.²⁴ Thus, Nrf2 has attracted attention as an effective target for NAFLD. Many Nrf2 activators have also been found and are used to stimulate Nrf2 expression to improve the cellular antioxidant ability against diseases.²⁵

Chemical Activators of Nrf2 in NAFLD

Flavonoids

Flavonoids are a class of bioactive antioxidants found in various fruits, vegetables, and plants.²⁶ Studies have shown their anti-inflammatory, antioxidant, and antitumor properties. Furthermore, flavonoids have also exhibited therapeutic properties in NAFLD by enhancing cellular antioxidant protection.^27,28 Meanwhile, many flavonoids have been proven to be Nrf2-ARE activators (Table 1).

Table 1

Chemical Activators of the Nrf2 Signaling Pathway in NAFLD.

Compounds	Treatment	Sample	Mechanism	Downstream	References
Acerola polysaccharides	200‐800 mg/kg/day for 9 weeks	C57BL/6 mice	Nrf2↑	HO-1, NQO1↑; SREBP1c↓;	²⁹
Apigenin	30 mg/kg/day for 3 weeks	C57BL/6J mice; Hepa1-6 cells	Nrf2-PPARγ↓	SOD, CAT, and GSH-Px↑	³⁰
Berberine	200 mg/kg/day for 16 weeks; 10 µM for 24 hours	Sprague-Dawley rats; human Huh7 cells	Nrf2↑, lncRNA MRAK052686↑	Unknown	³¹
Clusterin	Unknown	Hepatocyte-speciflic clusterin overexpression (hCLU-tg) mice	Nrf2 protein↑	HO-1 mRNA↑	³²
CPT	25‐100 mg/kg/day for 6 weeks	Specific pathogen-free grade male Wister rats	the protein and mRNA expression of Nrf2↑	HO-1, NQO1, SOD, GSH/GSSG↑; MDA↓	³³
Curcumin	50‐100 mg/kg/day for 8 weeks	C57BL/6 mice	Nrf2/FXR/LXRα↑	SREBP1c and FAS↓	³⁴
Curcumin	50 mg/kg/day for 6 weeks	Sprague-Dawley rats	Nuclei Nrf2↑	MDA↓; GSH, HO-1, and SOD↑	³⁵
Gastrodin	10‐50 mg/kg/day for 10 weeks; 50‐100 μg/mL for 24 hours	C57BL/6J mice; HL-7702 cells	AMPK/Nrf2 Pathway ↑	HO-1, SOD↑; MDA, ROS↓	³⁶
Green tea extract	0%-2% (w/w) for 8 weeks; 0‐5 μM for 2 hours	C57BL/6 mice; HC-04 cells	Nrf2↑	NADPH, quinone oxidoreductase-1 mRNA↑	³⁷
HHW	0.8 mM for 6 weeks	C57BL/6 mice	Nrf2 ↑, miR-136↓	ALT, AST, TG, TC↓	³⁸
Lemon balm extract ALS-L1023	0.8% (w/w) for 15 weeks	C57BL/6J mice	Nrf2↑	SOD2 and pAKT↑	³⁹
LFP	25‐50 mg/kg/day for 8 weeks	C57BL/6J male mice	Nrf2 nuclear translocation↑	Unknown	⁴⁰
Mono HER	500 mg/kg/day for 3 weeks	C57BL/6J mice	Nrf2↑	GSH/GSSG, HO-1, and Gpx3 gene↑	²⁷
NK-252	20 mg/kg/day for weeks	Fischer rats; Huh-7.5 cells	Interacting with the domain containing the Nrf2-binding site of keap1	NQO1 and carbonyl↓	⁴¹
Osteocalcin	30 mg/kg/day for 9 weeks	C57/BL6J mice	Nrf2 nuclear translocation↑, JNK↓	CAT, SOD, and GPx ↑	⁴²
PE	150 mg/kg/day for 8 weeks	Sprague-Dawley rats	Nrf2↑	GSH/GSSG, SOD, HO-1, and NQO-1↑	⁴³
Resveratrol	0.4% resveratrol for 16 weeks	C57BL/6 mice	Nrf2 methylation↓	FAS and SREBP1c↓	⁴⁴
Scutellarin	12.5‐50 mg/kg/day for 8 weeks; 50‐200 μmol/L	C57BL/6J mice; HepG2 cells	PPARγ/PGC-1α-Nrf2 pathway↓	HO-1, GST, and NQO1↑; NF-κB, Keap1↓	⁴⁵
Scutellarin	50‐300 mg/kg/day for 4 weeks	Sprague-Dawley rats	PI3K/Akt↑	HO-1 and NQO1↑	⁴⁶
Silybin	105 mg/kg/day for 8 weeks	C57BL/6 mice	Nrf2↑	CYP2E1, 4-HNE↓; GPx and SOD, GCLM, GCLC, NQO1, HMOX1↑	⁴⁷
Swertiamarin	25, 50, and 100 mg/kg/day for 12 weeks	Adult male kunming mice	Nrf2 in hepatocyte nuclear and cytoplasm↑	SOD, CAT, and GSH-px↑	⁴⁸

Abbreviations: ↓:decrease; ↑:increase;AKT, protein kinase B; ALT, alanine transaminase; AMPK, adenosine monophosphate-activated protein kinase; AST, aspartate transaminase; CAT, catalase; CPT: triterpenic acids-enriched fractions from Cyclocarya paliurus;GPx, glutathione peroxidase; GSH, glutathione; GSSG, glutathione disulphide; HO-1, heme oxygenase 1; JNK, c-Jun N-terminal kinase; Keap1, Kelch-like-ECH-associated protein 1 ; LFP: polyphenol-rich loquat fruit extract;lncRNA, long noncoding RNA; MDA, malondialdehyde; mRNA, messenger RNA; NAFLD, nonalcoholic fatty liver disease; NF-κB, nuclear factor kappa B; NQO1, NAD(P)H quinone oxidoreductase 1; Nrf2, nuclear factor erythroid-derived 2-like 2; PE: punicalagin enriched pomegranate extract; PI3K, phosphatidylinositol 3‑kinase; PPAR, peroxisome proliferator-activated receptor; SOD, superoxide dismutase; TC, total cholestrol; TG, triglycerides.

7-Mono-O-(β-hydroxyethyl)-rutoside (MonoHER) has been reported to activate the antioxidant defense system of Nrf2 by improving the ratio of GSH/glutathione disulfide (GSSG) and increasing the expression levels of the HO-1 and glutathione peroxidase 3 (GPx3) genes in Ldlr^−/− mice.²⁷ Scutellarin (4′,5,6-trihydroxy flavonoid-7-glucuronide) increased the level of Nrf2 protein in C57BL/6J mice fed an HFD. Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol in serum were reduced in groups that were fed scutellarin. The authors proved that scutellarin could activate the peroxisome proliferator-activated receptor-gamma (PPARγ)-PGC-1a-Nrf2 pathway and accelerate the expression of HO-1, glutathione S transferase (GST), and NQO1, while it significantly inhibited NF-κB and Keap1 at the mRNA and protein levels.⁴⁵ Similarly, Fan et al reported that scutellarin prevented NAFLD based on activation with Nrf2, which increased the expression of HO-1 and NQO1, and the enhancing effect is possibly related to the phosphatidylinositol 3‑kinase/protein kinase B pathway.⁴⁶ Apigenin (4′,5,7-trihydroxyflavone), a flavonoid present in many fruits and leafy vegetables, can protect against HFD-induced hepatic steatosis in rats⁴⁹ and inhibit lipid peroxidation, thereby exerting protective effects against hepatic steatosis.⁵⁰ In a study, Feng et al found that apigenin promoted Nrf2 translocation into nuclei; increased the activities of antioxidative enzymes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) in vivo; attenuated the HFD-induced increase in TG; and modified hepatic pathological changes (steatosis, lipid droplets) in rats. Further mechanistic research verified that the role of apigenin in activating PPARγ was inhibited by binding with Nrf2.³⁰ Kumar et al found that 7,8-dihydroxyflavone had activity against alcohol-induced and HFD-induced liver toxicity via upregulation of Nrf2.⁵¹ According to the above results, flavonoids are effective in the treatment of NAFLD in animal models. However, the application of flavonoids in the clinical therapy of NAFLD needs more research. In particular, the potential involvement of general cytotoxicity toward normal cells should be fully excluded.

Curcumin

Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), extracted from the dry rhizome of Curcuma longa, exerts hepatoprotective effects by suppressing lipid synthesis.³⁴ Many studies have been reported that clarify the roles of Nrf2 activation and liver protection from curcumin against NAFLD.^34,35 Yan et al verified that curcumin could inhibit SREBP-1c and induce the expression of CYP3A and CYP7A1 and simultaneously stimulate the expression of Nrf2. The study revealed that curcumin modulated the Nrf2/FXR pathway and improved NAFLD.³⁴ In 1 study, the authors observed that curcumin could inhibit HFD-induced elevation of serum aminotransferases and lipids, decrease tumor necrosis factor-alpha, interleukin-6, and malondialdehyde (MDA) levels in serum and liver, and increase GSH, HO-1, and SOD levels in rats. The in vivo study also showed that curcumin treatment increased Nrf2 protein in liver cell nuclei in mouse livers. Hence, curcumin appeared to exert its effects, at least in part, by activating the Nrf2 signaling pathway.³⁵ Overall, curcumin is effective in animals with NAFLD. However, its specificity for Nrf2 activity needs to be further verified.

Triterpenic Acid-Enriched Fractions From Cyclocarya paliurus

Cyclocarya paliurus (CP) is a Chinese herb whose leaves have antioxidant, hypoglycemic, and hypolipidemic activities.^52

-55 Previous research has revealed that CP can improve NAFLD by increasing the impact of SOD and GSH-Px and decreasing MDA levels in rats.⁵⁶ Furthermore, the triterpenic acid-enriched fraction from CP (CPT) could also reduce the content of hepatic lipid peroxide in NAFLD rats.^33,57 In 1 study, the authors designed a study to illuminate the function and mechanism of CPT against NAFLD in vivo and in vitro. The study found that CPT could inhibit HFD-induced activities of alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) in serum; decrease TG, TC, and free fatty acid levels; increase SOD expression and the GSH/GSSG ratio; and reduce MDA levels in vivo. An in vitro study also showed that CPT increased the protein and mRNA expression of Nrf2, NQO1, and HO-1 in HepG2 cells, which could be blocked by the Nrf2 inhibitor brusatol.³³ Clearly, the mechanistic details of CPT actions in the Nrf2 pathway deserve further research.

Gastrodin

Gastrodin (GSTD), a water-soluble extract of the root of Gastrodia elata BI., is regarded as a treatment for nervous system diseases such as vertebral basilar artery insufficiency, vertigo, and epilepsy in the clinic in China.^58,59 The increase in SOD activity and decrease in ROS production and the levels of proinflammatory cytokines by using GSTD in neurons and brain tissues under pathological conditions proved the antioxidative activity of GSTD, and the activity was connected with the phenomenon of the Nrf2 pathway.^60

-64 Qu et al reported that GSTD had antioxidative activity and the ability to improve lipid metabolism in both oleic acid-induced HL-7702 cells and HFD-induced NAFLD mice by activating adenosine monophosphate-activated protein kinase and promoting the nuclear distribution of Nrf2.³⁶ The toxicity of GSTD deserves exploration in the future.

NK-252

NK-252 (12.5-100 μmol/L) is a well-known Nrf2 activator.⁴¹ It attenuated choline-deficient l-amino acid-defined diet-induced increases in serum ALT and AST activities and improved hepatic steatosis in male Fischer rats. A study showed that NK-252 upregulated NQO1 gene expression and downregulated the carbonyl content in the liver. The authors demonstrated that NK-252 could reduce the gene expression of fibrogenic mediators, such as transforming growth factor-beta 1 and collagen α1(I), in vivo. Therefore, NK-252, through the activation of Nrf2, has antifibrotic effects in a rat model of NASH.

Clusterin

Clusterin, a multifunctional glycoprotein isolated from ram rete testis fluid, is upregulated and plays vital role in liver diseases.^65,66 A study by Park et al suggested that clusterin could improve liver steatosis and hepatitis induced by a methionine and choline-deficient diet by increasing Nrf2 protein and HO-1 mRNA in mice.³² Meanwhile, the immune reactivity for NF-κB and F4/80 was lower in the livers of hepatocyte-specific clusterin-over expressing mice than in those of wild-type mice.

Osteocalcin

Previous research has proven that there is a negative correlation between serum osteocalcin levels and the concentrations of ALT and AST.⁶⁷ Osteocalcin treatment improved mouse hepatic TG accumulation and liver injury. The levels of MDA and the ratio of oxidized glutathione in the liver induced by HFD were significantly protected due to the treatment of osteocalcin. Research on the mechanism demonstrated that osteocalcin intervention not only promoted Nrf2 nuclear translocation but also inhibited phosphorylation of the c-Jun N-terminal kinase pathway in vivo.⁴²

Other Activators

A large number of other compounds/extracts, including black sesame seed extract,⁶⁸ green tea extract,³⁷ lemon balm extract ALS-L1023,³⁹ punicalagin-enriched pomegranate extract,⁴³ silybin,⁴⁷ polyphenol-rich loquat fruit extract,⁴⁰ berberine³¹, and chitosan oligosaccharide,⁶⁹ have been demonstrated to attenuate inflammation, steatosis, and liver fibrosis in various NAFLD models, which might be related to activating the Nrf2 antioxidant system (Table 1; Figure 3).

Figure 3

Natural compounds activating Nrf2 in NAFLD. ARE, antioxidativeresponse element; CPT, triterpenic acids-enriched fractions from Cyclocarya paliurus; Keap1, Kelchlike-ECH-associated protein 1; LFP, polyphenol-rich loquat fruit extract; Maf,musculoaponeurotic fibrosarcoma; MonoHER, 7-mono-O-(β-hydroxyethyl)-rutoside; NAFLD, nonalcoholicfatty liver disease; Nrf2, nuclearfactor erythroid-derived 2-like 2.

Conclusions

The contemporary pathophysiological model of NAFLD consists of parallel pathways with dynamic crosstalk that culminate in steatosis and inflammation and ultimately fibrosis, cirrhosis, and hepatocellular carcinoma. The accumulation of hepatocellular lipids is increased in obesity. Increased metabolism of hepatocellular lipid content in obesity induces the development of NAFLD. The detrimental effect of excess accumulation of lipids and their derivatives is related to NAFLD. The Nrf2-related antioxidant system has been verified to play key roles in promoting oxidative stress in NAFLD. Nrf2 activation could effectively ameliorate NAFLD-induced inflammation, serum and intrahepatic lipid levels, and pathological changes in the liver in vitro and in vivo, which indicates that Nrf2 is a promising target for NAFLD therapy. However, there are some difficulties that should be solved in future research.

First, current studies use animal or cell models of NAFLD to research the antioxidant stress role of Nrf2 activators. These data indicate that Nrf2 activators could improve NAFLD. However, it remains to be explored whether Nrf2 activators can prevent advanced stages of NAFLD, such as liver fibrosis and liver cirrhosis. It is also of great significance to use primate models to explore the roles of Nrf2 activators. Second, the authors did not exclude mechanisms other than the Nrf2 pathway. Third, the side effects of Nrf2 activators are not well researched. The poor bioavailability of some Nrf2 activators also obstructs their application in clinical NAFLD therapy. The most important point is that Nrf2 activators can promote the development of tumors and chemotherapy resistance. This relationship with cancer and the difficulties with Nrf2 activator use need to be explained by further research.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by the Zhejiang Provincial Natural Science Foundation-Zhejiang Pharmaceutical Society Joint Fund (No. LYY18H280004, LY17H290007) and the Special Research Project on Hospital Pharmacy of the Zhejiang Pharmaceutical Association (2018ZYY24). This project was supported by the National Natural Science Foundation of China (Grant No. 82074186). ”Ten thousand plan”- high level talents special support plan of Zhejiang province, China (Grant No. ZJWR0108035).

ORCID iD

Yinghua He

References

Musso

Gambino

Cassader

Pagano

. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617-649.doi:10.3109/07853890.2010.518623

21039302

Vanni

Bugianesi

Kotronen

De Minicis

Yki-Järvinen

Svegliati-Baroni

. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42(5):320-330.doi:10.1016/j.dld.2010.01.016

20207596

Younossi

ZM.

Loomba

Rinella

et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68(1):361-371.doi:10.1002/hep.29724

29222911

Itoh

Chiba

Takahashi

et al. An Nrf2/small maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236(2):313-322.doi:10.1006/bbrc.1997.6943

9240432

Maher

Yamamoto

. The rise of antioxidant signaling-the evolution and hormetic actions of Nrf2. Toxicol Appl Pharmacol. 2010;244(1):4-15.doi:10.1016/j.taap.2010.01.011

20122947

Chambel

SS.

Santos-Gonçalves

Duarte

. The dual role of Nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism. Biomed Res Int. 2015;2015:1-10.doi:10.1155/2015/597134

26120584

Glen

Floros

Day

Pryke

Guideline Development

Guideline Development Group . Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ. 2016;354:i4428.doi:10.1136/bmj.i4428

27605111

Videla

LA.

Rodrigo

Orellana

et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci. 2004;106(3):261-268.doi:10.1042/CS20030285

14556645

Liu

Baker

SS.

Baker

RD.

Zhu

. Antioxidant mechanisms in nonalcoholic fatty liver disease. Curr Drug Targets. 2015;16(12):1301-1314.doi:10.2174/1389450116666150427155342

25915484

10.

Yesilova

Yaman

Oktenli

et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100(4):850-855.doi:10.1111/j.1572-0241.2005.41500.x

15784031

11.

Kobayashi

Yamamoto

. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal. 2005;7(3-4):385-394.doi:10.1089/ars.2005.7.385

15706085

12.

Kobayashi

Yamamoto

. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul. 2006;46:113-140.doi:10.1016/j.advenzreg.2006.01.007

16887173

13.

Nioi

Nguyen

Sherratt

PJ.

Pickett

. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol. 2005;25(24):10895-10906.doi:10.1128/MCB.25.24.10895-10906.2005

16314513

14.

Michalopoulos

. Liver regeneration. J Cell Physiol. 2007;213(2):286-300.doi:10.1002/jcp.21172

17559071

15.

Johnsen

Murphy

Prydz

Kolsto

. Interaction of the CNC-bZIP factor TCF11/LCR-F1/Nrf1 with MafG: binding-site selection and regulation of transcription. Nucleic Acids Res. 1998;26(2):512-520.doi:10.1093/nar/26.2.512

9421508

16.

McMahon

Thomas

Itoh

Yamamoto

Hayes

. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem. 2004;279(30):31556-31567.doi:10.1074/jbc.M403061200

15143058

17.

Aleksunes

LM.

Manautou

. Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol. 2007;35(4):459-473.doi:10.1080/01926230701311344

17562481

18.

Yamamoto

Suzuki

Kobayashi

et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol. 2008;28(8):2758-2770.doi:10.1128/MCB.01704-07

18268004

19.

Rushmore

TH.

Morton

MR.

Pickett

. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem. 1991;266(18):11632-11639.1646813

20.

Sharma

RS.

Harrison

DJ.

Kisielewski

et al. Experimental nonalcoholic steatohepatitis and liver fibrosis areameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2). Cell Mol Gastroenterol Hepatol. 2018;5(3):367-398.doi:10.1016/j.jcmgh.2017.11.016

29552625

21.

Chowdhry

Nazmy

MH.

Meakin

et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med. 2010;48(2):357-371.doi:10.1016/j.freeradbiomed.2009.11.007

19914374

22.

Wang

Cui

et al. Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis. 2013;12:165. doi:10.1186/1476-511X-12-165

24188280

23.

Akiyama

Warabi

Okada

et al. Deletion of both p62 and Nrf2 spontaneously results in the development of nonalcoholic steatohepatitis. Exp Anim. 2018;67(2):201-218.doi:10.1538/expanim.17-0112

29276215

24.

S-O.

Bang

IH.

Bae

EJ.

Park

B-H

. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor. Faseb J. 2017;31(9):3999-4010.doi:10.1096/fj.201700098RR

28536120

25.

Chen

Wang

et al. Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD). Nutrients. 2017;9(2):96. doi:10.3390/nu9020096

26.

Van De Wier

Koek

GH.

Bast

Haenen

GRMM

. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr. 2017;57(4):834-855.doi:10.1080/10408398.2014.952399

25897647

27.

Lemmens

KJA.

van de Wier

Koek

et al. The flavonoid monoHER promotes the adaption to oxidative stress during the onset of NAFLD. Biochem Biophys Res Commun. 2015;456(1):179-182.doi:10.1016/j.bbrc.2014.11.055

25462563

28.

Wang

D-J.

Cai

Y-Q.

Pan

S-Z

et al. Effect of total flavone of Haw leaves on nuclear factor erythroid-2 related factor and other related factors in nonalcoholic steatohepatitis rats. Chin J Integr Med. 2018;24(4):265-271.doi:10.1007/s11655-016-2450-0

26919834

29.

Yin

Liu

et al. Acerola polysaccharides ameliorate high-fat diet-induced non-alcoholic fatty liver disease through reduction of lipogenesis and improvement of mitochondrial functions in mice. Food Funct. 2020;11(1):1037-1048.doi:10.1039/C9FO01611B

31819934

30.

Feng

et al. Apigenin, a modulator of PPARγ, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation. Biochem Pharmacol. 2017;136:136-149.doi:10.1016/j.bcp.2017.04.014

28414138

31.

Lee

DH.

Han

DH.

Nam

et al. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radic Biol Med. 2016;99:520-532.doi:10.1016/j.freeradbiomed.2016.09.009

27634173

32.

Park

J-S.

Shim

Y-J.

Kang

B-H.

Lee

W-K.

Min

B-H

. Hepatocyte-specific clusterin overexpression attenuates diet-induced nonalcoholic steatohepatitis. Biochem Biophys Res Commun. 2018;495(2):1775-1781.doi:10.1016/j.bbrc.2017.12.045

29229391

33.

Zhao

M-G.

Sheng

X-P.

Huang

Y-P

et al. Triterpenic acids-enriched fraction from Cyclocarya paliurus attenuates non-alcoholic fatty liver disease via improving oxidative stress and mitochondrial dysfunction. Biomed Pharmacother. 2018;104:229-239.doi:10.1016/j.biopha.2018.03.170

29775890

34.

Yan

Zhang

Wang

Xie

. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice. Biomed Pharmacother. 2018;105:274-281.doi:10.1016/j.biopha.2018.05.135

29860219

35.

Wang

. Liver injury attenuation by curcumin in a rat NASH model: an Nrf2 activation-mediated effect? Ir J Med Sci. 2016;185(1):93-100.doi:10.1007/s11845-014-1226-9

25385666

36.

L-L.

Jiang

W-X.

Jiang

J-D.

Kong

W-J

. Gastrodin ameliorates oxidative stress and proinflammatory response in nonalcoholic fatty liver disease through the AMPK/Nrf2 pathway. Phytother Res. 2016;30(3):402-411.doi:10.1002/ptr.5541

26634892

37.

Sapper

TN.

Mah

et al. Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFκB pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Mol Nutr Food Res. 2016;60(4):858-870.doi:10.1002/mnfr.201500814

26679056

38.

Wang

. High-content hydrogen water-induced downregulation of miR-136 alleviates non-alcoholic fatty liver disease by regulating Nrf2 via targeting MEG3. Biol Chem. 2018;399(4):397-406.doi:10.1515/hsz-2017-0303

29261513

39.

Kim

Lee

Lim

et al. The lemon balm extract ALS-L1023 inhibits obesity and nonalcoholic fatty liver disease in female ovariectomized mice. Food Chem Toxicol. 2017;106(Pt A):292-305.doi:10.1016/j.fct.2017.05.059

28571771

40.

Yang

Zhao

Wang

Zhang

Zhao

. Polyphenol-rich loquat fruit extract prevents fructose-induced nonalcoholic fatty liver disease by modulating glycometabolism, lipometabolism, oxidative stress, inflammation, intestinal barrier, and gut microbiota in mice. J Agric Food Chem. 2019;67(27):7726-7737.doi:10.1021/acs.jafc.9b02523

31203627

41.

Shimozono

Asaoka

Yoshizawa

et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol. 2013;84(1):62-70.doi:10.1124/mol.112.084269

23592516

42.

Zhang

et al. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK. Endocrine. 2016;53(3):701-709.doi:10.1007/s12020-016-0926-5

26994931

43.

Zou

Yan

Shi

et al. Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin. Antioxid Redox Signal. 2014;21(11):1557-1570.doi:10.1089/ars.2013.5538

24393106

44.

Hosseini

Teimouri

Shabani

et al. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. Int J Biochem Cell Biol. 2020;119:105667.doi:10.1016/j.biocel.2019.105667

31838177

45.

Zhang

Sun

et al. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway. Free Radic Res. 2018;52(2):198-211.doi:10.1080/10715762.2017.1422602

29400110

46.

Fan

Lin

et al. Scutellarin prevents nonalcoholic fatty liverdisease (NAFLD) and hyperlipidemia via PI3K/AKT-dependent activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in rats. Med Sci Monit. 2017;23:5599-5612.doi:10.12659/MSM.907530

29172017

47.

Weng

Wang

et al. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the NF-κB pathway. Dig Dis Sci. 2018;63(12):3398-3408.doi:10.1007/s10620-018-5268-0

30191499

48.

Yang

Wei

et al. Amelioration of nonalcoholic fatty liver disease by swertiamarin in fructose-fed mice. Phytomedicine. 2019;59:152782.doi:10.1016/j.phymed.2018.12.005

31005808

49.

Zhang

Zheng

Dong

et al. Effects of flavonoids from rosa laevigata michx fruit against high-fat diet-induced non-alcoholic fatty liver disease in rats. Food Chem. 2013;141(3):2108-2116.doi:10.1016/j.foodchem.2013.05.019

23870935

50.

Panda

Kar

Apigenin

. Apigenin (4',5,7-trihydroxyflavone) regulates hyperglycaemia, thyroid dysfunction and lipid peroxidation in alloxan-induced diabetic mice. J Pharm Pharmacol. 2007;59(11):1543-1548.doi:10.1211/jpp.59.11.0012

17976266

51.

Kumar

Dwivedi

DK.

Lahkar

Jangra

. Hepatoprotective potential of 7,8-dihydroxyflavone against alcohol and high-fat diet induced liver toxicity via attenuation of oxido-nitrosative stress and NF-κB activation. Pharmacol Rep. 2019;71(6):1235-1243.doi:10.1016/j.pharep.2019.07.002

31670060

52.

Xie

J-H.

Dong

C-jun.

Nie

S-P

et al. Extraction, chemical composition and antioxidant activity of flavonoids from Cyclocarya paliurus (Batal.) Iljinskaja leaves. Food Chem. 2015;186:97-105.doi:10.1016/j.foodchem.2014.06.106

25976797

53.

Yang

Z-W.

Ouyang

K-H.

Zhao

Chen

Xiong

Wang

W-J

. Structural characterization and hypolipidemic effect of Cyclocarya paliurus polysaccharide in rat. Int J Biol Macromol. 2016;91:1073-1080.doi:10.1016/j.ijbiomac.2016.06.063

27343704

54.

Jiang

Yao

Wang

et al. Cyclocarya paliurus extract modulates adipokine expression and improves insulin sensitivity by inhibition of inflammation in mice. J Ethnopharmacol. 2014;153(2):344-351.doi:10.1016/j.jep.2014.02.003

24530856

55.

Guan

X-L

et al. Hypoglycemic effects and constituents of the barks of Cyclocarya paliurus and their inhibiting activities to glucosidase and glycogen phosphorylase. Fitoterapia. 2011;82(7):1081-1085.doi:10.1016/j.fitote.2011.07.002

21784137

56.

Wang

Jiang

Fang

et al. Antihyperglycemic, antihyperlipidemic and antioxidant effects of ethanol and aqueous extracts of Cyclocarya paliurus leaves in type 2 diabetic rats. J Ethnopharmacol. 2013;150(3):1119-1127.doi:10.1016/j.jep.2013.10.040

24184190

57.

Lin

Z-F.

Jiang

C-H

et al. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in sprague dawley rats. Phytomedicine. 2016;23(12):1475-1483.doi:10.1016/j.phymed.2016.08.003

27765368

58.

Shen

. Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer’s disease. Neuropathology. 2014;34(4):370-377.doi:10.1111/neup.12115

24661139

59.

Wang

Liu

. Gastrodin ameliorates Parkinson’s disease by downregulating connexin 43. Mol Med Rep. 2013;8(2):585-590.doi:10.3892/mmr.2013.1535

23783886

60.

Dai

J-N.

Zong

Zhong

L-M

et al. Gastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulated microglia via MAPK pathways. PLoS One. 2011;6(7):e21891. doi:10.1371/journal.pone.0021891

21765922

61.

Wang

X-L.

Xing

G-H.

Hong

et al. Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson’s disease: involvement of ERK1/2-Nrf2 signaling pathway. Life Sci. 2014;114(2):77-85.doi:10.1016/j.lfs.2014.08.004

25132361

62.

Jiang

. Gastrodin inhibits glutamate-induced apoptosis of PC12 cells via inhibition of CaMKII/ASK-1/p38 MAPK/p53 signaling cascade. Cell Mol Neurobiol. 2014;34(4):591-602.doi:10.1007/s10571-014-0043-z

24619207

63.

Peng

Wang

Chen

et al. Gastrodin alleviates cerebral ischemic damage in mice by improving anti-oxidant and anti-inflammation activities and inhibiting apoptosis pathway. Neurochem Res. 2015;40(4):661-673.doi:10.1007/s11064-015-1513-5

25582916

64.

Zhao

Zou

et al. Gastrodin protect primary cultured rat hippocampal neurons against amyloid-beta peptide-induced neurotoxicity via ERK1/2-Nrf2 pathway. Brain Res. 2012;1482:13-21.doi:10.1016/j.brainres.2012.09.010

22982592

65.

Fritz

IB.

Burdzy

Sétchell

Blaschuk

. Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro. Biol Reprod. 1983;28(5):1173-1188.doi:10.1095/biolreprod28.5.1173

6871313

66.

Jones

SE.

Jomary

. Clusterin. Int J Biochem Cell Biol. 2002;34(5):427-431.doi:10.1016/S1357-2725(01)00155-8

11906815

67.

Yilmaz

Kurt

Eren

Imeryuz

. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand J Clin Lab Invest. 2011;71(8):631-636.doi:10.3109/00365513.2011.604427

21859358

68.

Yang

Wang

Zhang

Sun

. Black sesame seeds ethanol extract ameliorates hepatic lipid accumulation, oxidative stress, and insulin resistance in fructose-induced nonalcoholic fatty liver disease. J Agric Food Chem. 2018;66(40):10458-10469.doi:10.1021/acs.jafc.8b04210

30244573

69.

Tao

Sun

Liu

et al. Chitosan oligosaccharide attenuates nonalcoholic fatty liver disease induced by high fat diet through reducing lipid accumulation, inflammation and oxidative stress in C57BL/6 mice. Mar Drugs. 2019;17(11):645. doi:10.3390/md17110645

31744059

Chemical Activators of the Nrf2 Signaling Pathway in Nonalcoholic Fatty Liver Disease

Abstract

Keywords

Relationship Between NAFLD and the Nrf2 Pathway

Chemical Activators of Nrf2 in NAFLD

Flavonoids

Curcumin

Triterpenic Acid-Enriched Fractions From Cyclocarya paliurus

Gastrodin

NK-252

Clusterin

Osteocalcin

Other Activators

Conclusions

Footnotes

Declaration of Conflicting Interests

Funding

ORCID iD

References